SAN FRANCISCO, Nov. 2, 2021 /PRNewswire/ -- The global diabetes associated ophthalmic treatment market size is expected to reach USD 44.7 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.5% from 2021 to 2028.
Key Insights & Findings:
- The diabetic retinopathy segment has captured the largest revenue share in 2020 followed by diabetic associated macular degeneration and glaucoma
- The drugs segment dominated the market and accounted for the highest revenue share in 2020 owing to factors such as the presence of major key players operating in the global market, high adoption rate, increased clinical trials to develop innovative drugs
- The hospitals segment is predicted to witness the fastest growth rate over the forecast timeframe due to the increasing number of patient visits and advanced infrastructure in hospitals as compared to other healthcare facilities. An increasing number of hospital admissions of diabetes patients is boosting the demand for the segment, thereby propelling the growth
- North America
held the largest revenue share in the market and is expected to maintain its dominance over the forecast period
Read 178 page market research report, "Diabetes Associated Ophthalmic Treatment Market Size, Share & Trends Analysis Report By Type (Drugs, Devices), By Application (Dry Eye, Glaucoma, Diabetic Retinopathy, DAMD, Uveitis, Cataract), By End-use, By Region, And Segment Forecasts, 2021 - 2028", by Grand View Research
The increasing prevalence of type II diabetes, geriatric population, and availability of early detection techniques are some of the factors driving the growth. This is coupled with technological advancements and increasing awareness of early diagnostics to help increase the success rate of the available treatment options. An increasing number of clinical trials to assess new drugs and devices for the prevention and management of these ophthalmic conditions are expected to fuel market growth in upcoming years.
COVID-19 related diabetic and ophthalmic complications are expected to boost the market for diabetes associated ophthalmic treatment methods. COVID-19 has a long-term effect on diabetic conditions. This is expected to increase the demand for treatment procedures in upcoming years. An increasing number of initiatives being undertaken by governments and nonprofit organizations to increase diabetes associated ophthalmic disease awareness is expected to boost the adoption of devices used for the treatment. Furthermore, WHO and IDF are working together to prevent and control diabetes and ensure good quality of life for people worldwide by providing accessible treatment facilities.
Grand View Research has segmented the global diabetes associated ophthalmic treatment market on the basis of application, type, end-use, and region:
- Diabetes Associated Ophthalmic Treatment Application Outlook (Revenue, USD Million, 2017 - 2028)
- Dry Eye Syndrome
- Glaucoma
- Eye Allergy & Infection
- Diabetic Retinopathy
- Diabetic Associated Macular Degeneration
- Uveitis
- Cataract
- Diabetic Macular Edema
- Others
- Diabetes Associated Ophthalmic Treatment Type Outlook (Revenue, USD Million, 2017 - 2028)
- Drugs
- Devices
- Diabetes Associated Ophthalmic Treatment End-use Outlook (Revenue, USD Million, 2017 - 2028)
- Hospitals
- Ophthalmic Centers
- Ambulatory Surgical Centers
- Others
- Diabetes Associated Ophthalmic Treatment Regional Outlook (Revenue, USD Million, 2017 - 2028)
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
List of Key Players of Diabetes Associated Ophthalmic Treatment Market
- Alcon
- Johnson & Johnson Services, Inc.
- Bausch Health
- F. Hoffmann-La Roche Ltd
- Allergan
- Bayer AG
- Santen Pharmaceutical Co. Ltd.
- Novartis AG
- Pfizer, Inc.
- Genentech, Inc.
- Carl Zeiss Meditec
- Lumenis
- Ellex Medical Lasers Ltd.
- IRIDEX Corp.
- Topcon Corp.
- Abbott Medical Optics
- Quantel
Check out more studies related to diabetes treatment, conducted by Grand View Research:
- Diabetic Retinopathy Market – The global diabetic retinopathy market size was valued at USD 5.81 billion in 2016 and is anticipated to grow at a CAGR of 6.3% over the forecast period. Diabetic retinopathy is considered as a serious sight-threatening complication that results due to long term diabetes.
- Diabetic Foot Ulcer Treatment Market – The global diabetic foot ulcer treatment market size was valued at USD 3.6 billion in 2017. It is anticipated to expand at a CAGR of 8.2% over the forecast period. Rising prevalence of diabetes and rapidly growing geriatric population worldwide are among the primary growth stimulants for DFU treatment market.
- Diabetes Devices Market – The global diabetes devices market size was valued at USD 25.9 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 6.6% from 2021 to 2028. The market is primarily driven by factors such as an increase in technological advancements and rise in the incidence of obesity.
Browse through Grand View Research's coverage of the Global Medical Devices Industry
Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: [email protected]
Web: https://www.grandviewresearch.com
Follow Us: LinkedIn | Twitter
SOURCE Grand View Research, Inc.
![](https://rt.prnewswire.com/rt.gif?NewsItemId=IO60585&Transmission_Id=202111020505PR_NEWS_USPR_____IO60585&DateId=20211102)
Share this article